ASSOCIATION OF GHRELIN RECEPTOR AND INFLAMMATION IN PERI-ATRIAL ADIPOSE TISSUE FROM OBESE PATIENTS WITH POSTOPERATIVE ATRIAL FIBRILLATION.
adipose tissue macrophages (ATMs)
epicardial adipose tissue
growth hormone secretagogue receptor (GHS-R)
postoperative atrial fibrillation
right atrial appendages
Journal
Acta endocrinologica (Bucharest, Romania : 2005)
ISSN: 1841-0987
Titre abrégé: Acta Endocrinol (Buchar)
Pays: Romania
ID NLM: 101269720
Informations de publication
Date de publication:
Historique:
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. The increasing evidence supports links between inflammation and AF. There is evidence showing that obesity is a major cause of adipose tissue (AT) inflammation. Ghrelin (GHRL), through its growth hormone secretagogue receptor (GHS-R) present on adipose tissue macrophages (ATMs), could modulate AT inflammation. Our study aimed to evaluate the role of adipose tissue macrophages (ATMs) and their GHS-R in adipose tissue samples of right atrial appendages (RAA) biopsies. We obtained RAA biopsies from 10 obese patients, undergoing cardiac surgery for coronary artery bypass graft (CABG) and developing postoperative atrial fibrillation (POAF). The epicardial tissue samples were examined using immunohistochemistry to visualize and quantify CD68 and GSH-R expression of the ATMs. Histologically, the mean adipocyte diameter (MAD) of epicardial adipose tissue (EAT) was larger in EAT samples with inflammation as compared to EAT without inflammation (84.2 µm Increased epicardial fat area, macrophage infiltration, and GHS-R expression in epicardial ATMs appeared to be associated with postoperative atrial fibrillation in obese patients.
Identifiants
pubmed: 33363650
doi: 10.4183/aeb.2020.298
pii: aeb.2020.298
pmc: PMC7748232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
298-302Informations de copyright
©by Acta Endocrinologica Foundation.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Mol Cell Endocrinol. 2011 Jun 20;340(1):44-58
pubmed: 21565248
J Biol Chem. 2003 Jan 3;278(1):64-70
pubmed: 12414809
J Clin Invest. 2011 Jun;121(6):2094-101
pubmed: 21633177
Diabetes. 2007 Jan;56(1):16-23
pubmed: 17192460
Cardiovasc Res. 2004 Jun 1;62(3):481-8
pubmed: 15158140
Front Endocrinol (Lausanne). 2019 May 17;10:278
pubmed: 31156548
Cardiovasc Res. 2002 May;54(2):361-79
pubmed: 12062341
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Immunology. 2018 Dec;155(4):407-417
pubmed: 30229891
J Am Soc Nephrol. 2004 Nov;15(11):2792-800
pubmed: 15504932
Nutr Diabetes. 2013 Dec 23;3:e99
pubmed: 24366371
Cardiovasc Res. 2014 May 1;102(2):205-13
pubmed: 24648445
Cardiovasc Res. 2006 Jan;69(1):227-35
pubmed: 16226234
Aging (Albany NY). 2016 Jan;8(1):178-91
pubmed: 26837433